Sarepta therapeutics reports sustained functional improvement two years after treatment with srp-9001, its investigational micro-dystrophin gene therapy for duchenne muscular dystrophy

Sarepta therapeutics reports sustained functional improvement two years after treatment with srp-9001, its investigational micro-dystrophin gene therapy for duchenne muscular dystrophy.sarepta therapeutics inc - results demonstrate continued safety and tolerability of srp-9001 in four participants with duchenne.sarepta therapeutics inc - all four participants demonstrated improvements in nsaa scores compared to baseline.sarepta therapeutics inc - therapy was well-tolerated in all participants over two-year time period.sarepta therapeutics inc - there were no serious adverse events or evidence of complement activation for srp-9001.
SRPT Ratings Summary
SRPT Quant Ranking